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Abstract
We previously demonstrated that a loosely restricted 45%-carbohydrate diet led to greater
reduction in hemoglobin A1c (HbA1c) compared to high-carbohydrate diets in outpatients with
mild type 2 diabetes (mean HbA1c level: 7.4%) over 2 years. To determine whether good glycemic
control can be achieved with a 30%-carbohydrate diet in severe type 2 diabetes, 33 outpatients (15
males, 18 females, mean age: 59 yrs) with HbA1c levels of 9.0% or above were instructed to follow
a low-carbohydrate diet (1852 kcal; %CHO:fat:protein = 30:44:20) for 6 months in an outpatient
clinic and were followed to assess their HbA1c levels, body mass index and doses of antidiabetic
drugs. HbA1c levels decreased sharply from a baseline of 10.9 ± 1.6% to 7.8 ± 1.5% at 3 months
and to 7.4 ± 1.4% at 6 months. Body mass index decreased slightly from baseline (23.8 ± 3.3) to 6
months (23.5 ± 3.4). Only two patients dropped out. No adverse effects were observed except for
mild constipation. The number of patients on sulfonylureas decreased from 7 at baseline to 2 at 6
months. No patient required inpatient care or insulin therapy. In summary, the 30%-carbohydrate
diet over 6 months led to a remarkable reduction in HbA1c levels, even among outpatients with
severe type 2 diabetes, without any insulin therapy, hospital care or increase in sulfonylureas. The
effectiveness of the diet may be comparable to that of insulin therapy.
Background
Carbohydrate-restricted diets (CRDs) have been reported
to be effective for glycemic control [1-7] in type 2 diabetes
(T2DM). We recently demonstrated that a loosely
restricted 45%-carbohydrate diet (carbohydrate-reduced
diet: CRD) led to a significant reduction in hemoglobin
A1c (HbA1c) levels with a tapering off of sulfonylureas
compared to a 60%-carbohydrate diet (high-carbohydrate
diet: HCD) over 2 years among outpatients with mild
T2DM (mean HbA1c = 7.4%) [8].
Little is known about the long-term effects of CRDs on
patients with severe T2DM. We therefore tried to deter-
mine whether good glycemic control can be achieved with
a stricter CRD (30%-carbohydrate), even in outpatients
with severe T2DM in an outpatient clinic.
Patients and methods
We recruited outpatients with T2DM having HbA1c levels
of 9.0% or above between September 2005 and Septem-
ber 2007 in Haimoto Clinic, and followed their HbA1c
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levels, body mass index (BMI) and doses of antidiabetic
drugs monthly for 6 months. We also followed their
serum lipid profiles, serum creatinine and blood pressure.
Patients with serum creatinine levels > 1.5 mg/dl, severe
diabetes complications (proliferative retinopathy, symp-
tomatic neuropathy and diabetic foot), ketoacidosis, soft
drink ketosis [9] and malignant tumor were excluded. Five
patients who developed ketosis received fluid therapy for
a few days, and did not require any inpatient care or insu-
lin therapy. We intended to taper the dose of sulfonylu-
reas as soon as the patients' HbA1c levels were controlled,
and to prescribe metformin, acarbose and pioglitazone.
The patients were instructed to maintain their usual level
of physical activity throughout the study. Changes in
activity levels were investigated by questionnaire. The
study protocol was identical to that of the previous study
[8] and was approved by the Ethical Committee of the
Nagoya Tokusyukai General Hospital. All patients pro-
vided written informed consent.
The main principle of the CRD was to eliminate carbohy-
drate-rich food twice a day at breakfast and dinner, or
eliminate it three times a day at breakfast, lunch and din-
ner. Table 1 shows the list of foods that the subjects were
instructed to avoid. There were no other restrictions.
Patients on the CRD were permitted to eat as much pro-
tein and fat as they wanted, including saturated fat. Their
details were described previously [8]. At the end of the
study, dietary intake was assessed based on 3-day food
records. Changes in HbA1c and BMI were assessed by the
Friedman test, and changes in serum LDL-cholesterol,
HDL-cholesterol, triglyceride, creatinine and blood pres-
sure were assessed by the paired t-test.
Results
Thirty-three patients participated in this study. Back-
ground characteristics of the patients are shown in Table
2. Two patients (6%) on the CRD dropped out after 4
months. Of the remaining 31 patients, the total energy
intake (mean ± SD) was 1852 ± 549 kcal/day (Table 3).
The daily average intakes of carbohydrate, fat and protein
were 137 ± 41 g (30 ± 10% of total energy), 91 ± 34 g (44
± 10%) and 91 ± 30 g (20 ± 4%), respectively, with the
mean fiber intake being 14 ± 6 g. The carbohydrates were
mainly derived from rice and noodles made from wheat
or buckwheat, and also from potatoes, fruits, bread and
confectioneries.
The mean HbA1c level decreased sharply from baseline
(10.9 ± 1.6%) to 7.8 ± 1.5% at 3 months, and then more
gradually to 7.4 ± 1.4% at 6 months (P < 0.001) (Table 4
and Figure 1). BMI slightly decreased over 6 months, but
the decrease did not reach statistical significance (P  =
0.057) (Table 4 and Figure 2). HbA1c levels of the two
drop-out patients were 13.0% and 9.5% at baseline,
which decreased to 8.6% and 8.1% after 3 months but
returned to 12.6% and 8.6% after 6 months, respectively.
When the two patients were excluded, the mean HbA1c
level after 6 months was 7.2 ± 1.0%. No adverse effect was
observed except for mild constipation. One female patient
had an increased physical activity level during the study
period in spite of our instructions. However, her increase
in physical activity was no more than one hour of walking
per day, four days a week. She had implemented an 11%-
carbohydrate diet without any antidiabetic drug, and her
HbA1c level decreased from 14.4% at baseline to 6.1%
after 3 months and had been maintained at 5.5% after 6
months.
Ten patients had already been prescribed antidiabetic
drugs by other physicians at baseline. The number of
patients who were on sulfonylureas decreased over 6
months (glibenclamide: from 6 to 1, glimepiride: from 1
to 0, tolbutamide: from 0 to 1) (Table 4). Of the 31
patients, 12 received other antidiabetic drugs at the end of
the study; a relatively low dose of metoformin or miglitol
was mainly prescribed. No patient required inpatient care
or insulin therapy.
Excluding 4 patients who were prescribed the lipid-lower-
ing drugs during the study period, the mean serum LDL-
cholesterol levels of the subjects decreased (P = 0.036)
(Table 4 and Figure 3), while their mean HDL-cholesterol
levels increased (P = 0.008) over 6 months (Table 4 and
Figure 4). The mean serum triglyceride concentrations
decreased over 6 months, but the change did not reach
statistical significance (P = 0.39) (Table 4). We found no
significant change in serum creatinine. Eleven patients
were prescribed antihypertensive drugs during the study
period. No significant change was detected in systolic and
diastolic blood pressure.
Table 1: Carbohydrate-rich foods instructed to remove in the carbohydrate-reduced diet
Staple foods rice, bread, corn, spaghetti, noodle made of wheat or buckwheat, potato, sweet potato, taro and yam
Fruits pear, apple, persimmon, mikan, orange, grapefruit, peach, grape, melon, water melon, banana, pine apple and Japanese chestnut, 
etc.
Vegetables carrot, Indian lotus, pumpkin and autumn squash
Confectioneries
Drink beverages containing sugar, glucose and fructose, and milk
Alcohol brew: sake, beer and wine (Distilled liquor was not restricted.)Nutrition & Metabolism 2009, 6:21 http://www.nutritionandmetabolism.com/content/6/1/21
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Discussion
This study demonstrated that good glycemic control with
a tapering off of sulfonylureas and improvement of the
serum cholesterol profile can be achieved with a 30%-car-
bohydrate diet among outpatients with severe T2DM at an
outpatient clinic. The mean HbA1c level decreased by
1.0% per month during the first 3 months. Our results
must be cautiously interpreted due to the lack of a control
group. However, it can be difficult to decrease HbA1c by
3.5% by means of HCDs over 6 months without any inpa-
tient care, insulin therapy or reinforcement of sulfonylu-
reas. When HCDs were incorporated into the dietary
therapy for severe T2DM, the expected decreases in HbA1c
levels for the insulin therapy ranged from 1.5% to 2.5%,
while that for oral sulfonylureas was about 1.5% in T2DM
[10]. Moreover, practitioners in Japan have achieved
HbA1c levels ranging from 7.6 to 7.7% by means of insu-
lin treatment or insulin plus oral antidiabetic drugs
among patients with severe T2DM [11]. Thus, the effec-
tiveness of the 30%-carbohydrate diet could be compared
to that of the insulin therapy with HCDs, so that CRD can
be considered an alternative to conventional HCDs in the
dietary management of T2DM.
When total energy intake is strictly restricted, there may be
little difference in glycemic control between CRDs and
HCDs [12]. In contrast, CRD has the advantage that is
does not restrict fat and protein and does not require
explicit attention to total energy intake [8], giving rise to a
Individual changes in body mass index over 6 months (n = 33) Figure 2
Individual changes in body mass index over 6 months 
(n = 33). Two drop-out patients were included.
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Table 2: Background characteristics in all patients (n = 33)
Age (years) 59 ± 9
Male/Female (n) 15/18
Duration of diabetes (months) 59 ± 9
Body weight (kg) 60.9 ± 11.0
Body mass index 23.8 ± 3.3
Hemoglobin A1c (%) 10.9 ± 1.6
Serum LDL-cholesterol (mg/dl) 147 ± 50
Serum HDL-cholesterol (mg/dl) 51 ± 14
Serum triglyceride (mg/dl) 187 ± 177
Serum creatinine (mg/dl) 0.68 ± 0.20
Systolic blood pressure (mmHg) 138 ± 17
Diastolic blood pressure (mmHg) 81 ± 11
Patients with medications (n)
Antidiabetic drugs 10
Antihypertensive drugs 11
Lipid-lowering drugs 4
Plus-minus values indicate means ± SD
Table 3: Daily dietary intake at 6 months from baseline (n = 31)
Total energy intake (kcal) 1852 ± 549
Carbohydrate (g) 137 ± 41
Fiber (g) 14 ± 6
Carbohydrate (% energy) 30 ± 10
Fat (g) 91 ± 34
Saturated fat (g) 26 ± 13
Monounsaturated fat (g) 35 ± 16
Polyunsaturated fat (g) 17 ± 7
Fat (% energy) 44 ± 10
Protein (g) 91 ± 30
Protein (% energy) 20 ± 4
Foods rich in carbohydrate (g)
Rice 132 ± 86
Noodles 25 ± 43
Bread 15 ± 29
Potatoes 11 ± 18
Fruit 39 ± 54
Confectioneries 12 ± 20
Sugar 7 ± 6
Plus-minus values indicate means ± SD.
Two drop-out patients are excluded.
Individual changes in hemoglobin A1c over 6 months (n = 33) Figure 1
Individual changes in hemoglobin A1c over 6 months 
(n = 33). Two drop-out patients were included.
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low attrition rate of 6% over 6 months. Beyond calorie
restriction, CRD has an advantage in comparison to
HCDs, in that dietary fat and protein have little effect on
postprandial blood glucose levels, while dietary carbohy-
drate is a major stimulus [3,4].
The attrition rate for CRD was lower than that in other
studies on CRDs (22% for 3 months, and 45%, 33% and
27% for 6 months) [7,12-14]. It should also be noted that
the attrition rate in the previous study on CRD was lower
in the first year (8%) but higher in the second year (33%)
[8]. This is probably due to reduced motivation because of
the improvement of glycemic control during the first year.
In conclusion, the 30%-carbohydrate diet led to a remark-
able reduction in HbA1c levels from baseline to 6 months,
Individual changes in serum HDL-cholesterol concentrations  over 6 months (n = 29) Figure 4
Individual changes in serum HDL-cholesterol concen-
trations over 6 months (n = 29). Four patients were 
excluded because they received lipid-lowering drugs.
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Table 4: Changes in HbA1c, BMI, serum lipids and creatinine, blood pressure and dose of antidiabetic drugs (n = 33)
Baseline After 3 months After 6 months P
HbA1c (%) 10.9 ± 1.6 (9.0 – 14.4) 7.8 ± 1.5 (5.9 – 11.3) 7.4 ± 1.4 (5.5 – 12.7) < 0.001
BMI 23.8 ± 3.3 (18.0 – 33.8) 23.5 ± 3.4 (16.8 – 32.8) 23.5 ± 3.4 (17.1 – 32.7) 0.057
Serum LDL-cholesterol (mg/dl)* 142 ± 50 (51 – 260) 128 ± 34 (61 – 213) 0.036
Serum HDL-cholesterol (mg/dl)* 52 ± 14 (30 – 77) 59 ± 16 (34 – 94) 0.008
Serum triglyceride (mg/dl)* 182 ± 189 (50 – 823) 157 ± 178 (34 – 721) 0.39
Serum creatinine (mg/dl) 0.68 ± 0.20 (0.38 – 1.20) 0.71 ± 0.21 (0.44 – 1.25) 0.21
Systolic BP (mmHg) 138 ± 17 (104 – 175) 135 ± 14 (97 – 157) 0.24
Diastolic BP (mmHg) 81 ± 11 (59 – 102) 81 ± 11 (48 – 113) 0.64
Patients with antidiabetic drugs (n)
Glibenclamide n = 6 (4.0 mg) n = 3 (1.7 mg) n = 1 (2.5 mg)
Glimepiride n = 1 (3.0 mg) n = 2 (0.75 mg) n = 0 (0 mg)
Tolbutamide n = 0 (0 mg) n = 0 (0 mg) n = 1 (500 mg)
Metformin n = 0 (0 mg) n = 2 (500 mg) n = 5 (600 mg)
Nateglinide n = 2 (135 mg) n = 2 (180 mg) n = 0 (0 mg)
Pioglitazone n = 0 (0 mg) n = 0 (0 mg) n = 2 (30 mg)
Miglitol n = 1 (150 mg) n = 3 (100 mg) n = 7 (125 mg)
HbA1c: hemoglobin A1c; BMI: body mass index; BP: blood pressure. Values are means ± SD. The numbers in parenthesis in HbA1c, BMI, serum 
lipids, serum creatinine and blood pressure indicate ranges, and those in antidiabetic drugs show a mean daily dose. Two drop-out patients are 
included in the analysis.
*: Four patients are excluded from serum lipids analysis because they received lipid-lowering drugs.
Individual changes in serum LDL-cholesterol concentrations  over 6 months (n = 29) Figure 3
Individual changes in serum LDL-cholesterol concen-
trations over 6 months (n = 29). Four patients were 
excluded because they received lipid-lowering drugs.
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together with improvement of serum cholesterol levels
without any insulin therapy, hospital care or reinforce-
ment of sulfonylureas, even among outpatients with
severe T2DM. The effectiveness of the diet may be compa-
rable to that of insulin therapy. CRD could be imple-
mented with good compliance among outpatients;
therefore, it can be an alternative to HCDs in the dietary
management of T2DM.
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